Robert M. Davis
Chairman and Chief Executive Officer, Merck
In the news
Merck splits Human Health into Oncology and Specialty units and names new commercial leaders
Merck reorganized its Human Health business into an Oncology unit and a Specialty, Pharma and Infectious Diseases unit, and created a Strategic Access, Policy and Communications group.
Management
Merck reports Q4 2025 results and gives 2026 guidance of $65.5B-$67.0B sales and $5.00-$5.15 non-GAAP EPS
Merck reported fourth-quarter 2025 sales of $16.4 billion, up 5%, and full-year 2025 sales of $65.0 billion, up 1%.
Earnings